SFTPC and interstitial lung disease: Furthermore, since our group previously established methods for generating human induced pluripotent stem cells (iPSC)-derived alveolar cells in organoids,16,17 AT2 cells differentiated from patient-specific iPSC harboring SFTPC mutations that cause ILD were used to evaluate the efficacy of the candidate compounds, and we identified Cryptotanshinone (CPT) as a potential therapeutic agent for ILD.